J
Jeroen Huizingh
Researcher at Janssen Pharmaceutica
Publications - 7
Citations - 600
Jeroen Huizingh is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Hemagglutinin (influenza) & Antigen. The author has an hindex of 7, co-authored 7 publications receiving 462 citations. Previous affiliations of Jeroen Huizingh include Johnson & Johnson & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.
Antonietta Impagliazzo,Fin Milder,Harmjan Kuipers,Michelle Wagner,Xueyong Zhu,Ryan M. B. Hoffman,Ruud van Meersbergen,Jeroen Huizingh,Patrick Wanningen,Johan Verspuij,Martijn de Man,Zhaoqing Ding,Adrian Apetri,Başak Kükrer,Eveline Sneekes-Vriese,Danuta Tomkiewicz,Nick S. Laursen,Peter Lee,Anna Zakrzewska,Liesbeth Dekking,Jeroen Tolboom,Lisanne Tettero,Sander van Meerten,Wenli Yu,Wouter Koudstaal,Jaap Goudsmit,Andrew B. Ward,Wim Meijberg,Ian A. Wilson,Katarina Radosevic +29 more
TL;DR: The results represent a proof of concept for the design of HA stem mimics that elicit bnAbs against influenza A group 1 viruses and completely protects mice in lethal heterologous and heterosubtypic challenge models, and reduces fever after sublethal challenge in cynomolgus monkeys.
Journal ArticleDOI
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
Laura Solforosi,Harmjan Kuipers,Mandy Jongeneelen,Sietske K. Rosendahl Huber,Joan E.M. van der Lubbe,Liesbeth Dekking,Dominika N. Czapska-Casey,Ana Izquierdo Gil,Miranda R.M. Baert,Joke Drijver,Joost Vaneman,Ella van Huizen,Ying Choi,Jessica Vreugdenhil,Sanne Kroos,Adriaan H. de Wilde,Eleni Kourkouta,Jerome Custers,Remko Van Der Vlugt,Daniel Veldman,Jeroen Huizingh,Krisztian Kaszas,Tim J. Dalebout,Sebenzile K. Myeni,Marjolein Kikkert,Eric J. Snijder,Dan H. Barouch,Kinga P. Böszörményi,Marieke A. Stammes,Ivanela Kondova,Ernst J. Verschoor,Babs E. Verstrepen,Gerrit Koopman,Petra Mooij,Willy M. J. M. Bogers,Marjolein van Heerden,Leacky Muchene,Jeroen Tolboom,Ramon Roozendaal,Boerries Brandenburg,Hanneke Schuitemaker,Frank Wegmann,Roland Zahn +42 more
TL;DR: In this paper, a two-dose Ad26.COV2.S vaccine candidate was evaluated in adult and aged nonhuman primates (NHPs) and showed that two doses may improve the magnitude and durability of immunity and protective efficacy.
Posted ContentDOI
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
Mandy Jongeneelen,Krisztian Kaszas,Veldman D,Jeroen Huizingh,van der Vlugt R,Schouten T,David Zuijdgeest,Uil T,van Roey G,Nuria Guimera,Navis M,Rinke Bos,le Gars M,Jerry Sadoff,Leacky Muchene,Jaroslaw Juraszek,Johannes P. M. Langedijk,Ronald Vogels,Jerome Custers,Hanneke Schuitemaker,Boerries Brandenburg +20 more
TL;DR: In this paper, sera from recipients of a single dose of our Ad26.S COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants of concern.
Journal ArticleDOI
Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice
Joan E. M. van der Lubbe,Johan W. A. Verspuij,Jeroen Huizingh,Sonja P. R. Schmit-Tillemans,Jeroen Tolboom,Liesbeth Dekking,Ted Kwaks,Börries Brandenburg,Wim Meijberg,Roland Zahn,Ramon Roozendaal,Harmjan Kuipers +11 more
TL;DR: It is shown in mice that in a direct comparison to H1 FL HA, using the same immunization regimen, dosing and adjuvant, a group 1 mini-HA has a higher protective efficacy against group 1 influenza virus challenges not homologous to the H1FL HA.
Journal ArticleDOI
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge
Joan E. M. van der Lubbe,Jeroen Huizingh,Johan W. A. Verspuij,Lisanne Tettero,Sonja P. R. Schmit-Tillemans,Petra Mooij,Daniella Mortier,Gerrit Koopman,Willy M. J. M. Bogers,Liesbeth Dekking,Wim Meijberg,Ted Kwaks,Boerries Brandenburg,Jeroen Tolboom,Hanneke Schuitemaker,Ramon Roozendaal,Harmjan Kuipers,Roland Zahn +17 more
TL;DR: It is shown that mini-HA, compared to a trivalent influenza vaccine (TIV), elicits a broadened influenza-specific humoral immune response in NHP previously exposed to influenza, and the immune response elicited by the novel vaccine surpassed that of a standard seasonal influenza vaccine.